Table 2.
Patient Outcomes After FCC HSCT
| Outcome | Value |
| Time to neutrophil count >0.5 × 109/L, d, median (range) | 12 (10-22) |
| Time to platelet count >20 × 109/L, d, median (range) | 12 (9-61) |
| Primary graft failure, n (%) | 1 (2.2) |
| Acute GVHD, n (%) | 6 (13.3) |
| Grade I/II | 6 |
| Grade III/IV | 0 |
| Chronic GVHD, n (%) | 6 (13.3) |
| Mild | 4 |
| Moderate | 1 |
| Severe | 1 |
| 1-year TRM, n (%) | 3 (6.6) |
| 5-year OS, % | 93.1 |
| 5-year EFS, % | 90.7 |
| 5-year EFS, MSD (n = 12) versus UD (n = 33), % | 100 versus 87.4 (P = .219) |
| 5-year EFS, age ≤50 yr (n = 31) versus >50 yr (n = 14), % | 93 versus 85.7 (P = .356) |
FCC indicates fludarabine, cyclophosphamide, and alemtuzumab (Campath-1H); HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; TRM, transplantation-related mortality; OS, overall survival; EFS, event-free survival; MSD, matched sibing donor; UD, unrelated donor.